Financial Compliance in Clinical Trials

Barbara K. Martin ()
Additional contact information
Barbara K. Martin: Penn Medicine Lancaster General Health, Administrative Director, Research Institute

Chapter 27 in Principles and Practice of Clinical Trials, 2022, pp 521-539 from Springer

Abstract: Abstract Financial compliance considerations are an important aspect of the design and funding of clinical trials. Such research often involves a mixture of sponsor funding and insurance billing for the clinical services provided in the trial. In the United States, what can be billed to insurance and what must be paid by a sponsor are in general determined by the Centers for Medicare & Medicaid Services (CMS). Other third-party payer policies largely mimic those of CMS. Medicare reimbursement for clinical trials is determined by the interagency agreement between the Food and Drug Administration and CMS regarding investigational devices, the clinical trials policy, and CMS guidance on coverage with evidence development. Non-compliance in research billing carries risk of monetary penalty. To ensure compliance, providers and institutions must conduct coverage analyses to determine if a trial qualifies for CMS coverage and, if it does, which clinical items and services can be billed to CMS. Claims with items and services being billed to CMS must be identified with research codes and modifiers. While these policies and procedures have brought some clarity to research billing, there are still murky waters that providers and institutions need to navigate. The risk from non-compliance is not theoretical. Several cases of large fines to major research institutions have been well publicized. The imperative for having a comprehensive program for billing compliance continues to mount, and the cost of this necessary infrastructure must be part of the calculation of institutional overhead for clinical research.

Keywords: Billing compliance; Coverage analysis; Clinical Trial Policy; Coverage with evidence development; Qualifying clinical trials; Waiving of co-pays; Subject remuneration; Subject injury (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-319-52636-2_267

Ordering information: This item can be ordered from
http://www.springer.com/9783319526362

DOI: 10.1007/978-3-319-52636-2_267

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().